Hengrui Medicine (600276.SH) subsidiary HRS-3095 tablets received approval notice for drug clinical trials.

Wisdom Finance APP News, Hengrui Medicine (600276.SH) announced that recently, its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice for HRS-3095 tablets issued by the National Medical Products Administration (referred to as the "NMPA"), and will soon conduct clinical trials. The indication applied for is for patients with chronic idiopathic urticaria (CIU).